Cancer in Ireland

IARC estimates 30,752 new cancer cases and 10,914 cancer deaths in Ireland in 2024; the commonest new cancers are prostate, breast and trachea, bronchus and lung. This page is assembled automatically from OnCo's data: 243 trials with a site there, 10 institutions, 7 companies, 14 people and 1 programme or law, and says what OnCo does not yet hold.

Cancer figures, GLOBOCAN 2024

Compare countries →

New cases

30,752

all cancers

Deaths

10,914

all cancers

Incidence rate

317.0

per 100,000, age-standardised

Mortality rate

92.6

per 100,000, age-standardised

Cumulative risk

30.6%

of a cancer by age 74

Population

5,255,020

IARC, 2024

Most new cases

Site	New cases	Rate	OnCo page
Prostate	4,183	95.2	Prostate cancer
Breast	3,663	84.5	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Trachea, bronchus and lung	2,833	26.5	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	2,796	27.7	Colorectal cancer
Melanoma of skin	1,471	16.0	Melanoma
Bladder	1,029	9.2	Bladder & urothelial cancer
Non-Hodgkin lymphoma	1,002	10.4	Non-Hodgkin lymphoma (all types), Diffuse large B-cell lymphoma
Kidney	804	8.9	Renal cell carcinoma
Pancreas	722	6.5	Pancreatic ductal adenocarcinoma
Corpus uteri	674	14.4	Endometrial cancer

Most deaths

Site	Deaths	Rate	OnCo page
Trachea, bronchus and lung	1,931	16.8	Lung cancer (all types), Non-small-cell lung cancer, Small-cell lung cancer
Colorectum	1,223	10.0	Colorectal cancer
Breast	810	14.1	Triple-negative breast cancer (TNBC), HR-positive / HER2-negative breast cancer, HER2-positive breast cancer
Prostate	660	9.8	Prostate cancer
Pancreas	657	5.5	Pancreatic ductal adenocarcinoma
Oesophagus	510	4.4	Oesophageal cancer
Liver and intrahepatic bile ducts	497	4.3	Hepatocellular carcinoma
Stomach	356	3.1	Gastric & gastro-oesophageal junction cancer
Brain, central nervous system	338	3.9	Glioma & glioblastoma
Ovary	322	5.6	Ovarian cancer

Incidence: method 1, trends in national rates projected to 2024.
Mortality: method 1, trends in national rates projected to 2024.
Rates are age-standardised per 100,000 (World standard population), both sexes, all ages. Non-melanoma skin cancer is left out of the site lists, as on the deep dives. IARC lists the country as “Ireland”, in Northern Europe (Europe), Very High HDI, high income.
Source: Ervik M, Laversanne M, Lam F, Colombet M, Ferlay J, Filho AM, Bray F (2026). Global Cancer Observatory: Cancer Today (2024 estimates, version 1.0). Lyon, France: International Agency for Research on Cancer. https://gco.iarc.who.int/today, read through the IARC API on 2026-11-04.

Trials with a site here

243 trials in OnCo · 71 recruiting overall

243 trials

Trial			Lead sponsor
(HARBOR) Study to Evaluate Efficacy and Safety of BLU-263 Versus Placebo in Patients With Indolent Systemic Mastocytosis NCT04910685	Phase 2/3	Recruiting	Blueprint Medicines Corporation	88	2026-10-07
A Study of Avutometinib (VS-6766) + Defactinib (VS-6063) in Recurrent Low-Grade Serous Ovarian Cancer NCT06072781	Phase 3	Recruiting	Verastem, Inc.	106	2026-10-07
A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Pa NCT06091865	Phase 3	Recruiting	Regeneron Pharmaceuticals	194	2026-10-07
Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pemb NCT03486873	Phase 3	Recruiting	Merck Sharp & Dohme LLC	782	2026-10-07
A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001) NCT06925737	Phase 3	Recruiting	Merck Sharp & Dohme LLC	298	2026-10-06
A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02) NCT06863272	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	82	2026-10-06
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Canc NCT07216703	Phase 3	Recruiting	Merck Sharp & Dohme LLC	180	2026-10-06
A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021) NCT07318558	Phase 3	Recruiting	Merck Sharp & Dohme LLC	165	2026-10-06
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Particip NCT06793215	Phase 3	Recruiting	Hoffmann-La Roche	288	2026-10-06
A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680	Phase 2	Recruiting	Bristol-Myers Squibb	58	2026-10-06
A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004) NCT06136650	Phase 3	Recruiting	Merck Sharp & Dohme LLC	330	2026-10-06
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010) NCT06312176	Phase 3	Recruiting	Merck Sharp & Dohme LLC	259	2026-10-06
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participan NCT06952504	Phase 3	Recruiting	Merck Sharp & Dohme LLC	265	2026-10-06
A Study to Evaluate the Efficacy and Safety of Sacituzumab Tirumotecan (MK-2870) Maintenance Treatment Versus Standard of Care in Participants With Pl NCT06824467	Phase 3	Recruiting	Merck Sharp & Dohme LLC	197	2026-10-06
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-287 NCT06422143	Phase 3	Recruiting	Merck Sharp & Dohme LLC	216	2026-10-06
Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) NCT06393374	Phase 3	Recruiting	Merck Sharp & Dohme LLC	314	2026-10-06
Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003) NCT06136624	Phase 3	Recruiting	Merck Sharp & Dohme LLC	288	2026-10-06
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A) NCT06353386	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	77	2026-10-06
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003) NCT04728893	Phase 2	Recruiting	Merck Sharp & Dohme LLC	121	2026-10-05
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer NCT06982521	Phase 3	Recruiting	Relay Therapeutics, Inc.	243	2026-10-05
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009) NCT06623422	Phase 3	Recruiting	Merck Sharp & Dohme LLC	242	2026-10-02
FORTIFI-HN01 NCT06788990	Phase 2/3	Recruiting	Bicara Therapeutics	231	2026-10-02
A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Re NCT05519085	Phase 3	Recruiting	Celgene	266	2026-09-30
A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell NCT07361497	Phase 3	Recruiting	Bristol-Myers Squibb	260	2026-09-30
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment NCT07472517	Phase 3	Recruiting	Boehringer Ingelheim	245	2026-09-29
Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301) NCT06881784	Phase 3	Recruiting	Revolution Medicines, Inc.	158	2026-09-29
A Clinical Study to Assess the Efficacy of Adjuvant Immunotherapy With Cemiplimab in Patients With Surgically Removed Non-small Cell Lung Cancer Who Have Not Re NCT06931717	Phase 3	Recruiting	ETOP IBCSG Partners Foundation	35	2026-09-28
A Study of GSK5764227 in Participants With Relapsed Small Cell Lung Cancer (SCLC) NCT07099898	Phase 3	Recruiting	GlaxoSmithKline	135	2026-09-28
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL) NCT06943872	Phase 3	Recruiting	BeOne Medicines	195	2026-09-28
An Early Phase Trial of RPTR-1-201 in Advanced Solid Tumors NCT07293754	Phase 1/2	Recruiting	Repertoire Immune Medicines	12	2026-09-28

(showing the first 30)

Trial records in OnCo whose ClinicalTrials.gov entry lists at least one site in Ireland, captured 2026-10-07 to 2026-10-10. Recruiting first, then the most recently updated. The status is the study's overall status; whether a site in Ireland is open is on the registry page, under Contacts and Locations.

Institutions, companies and people

Screening, vaccination and law

Term

Ireland: Public Health (Alcohol) Act 2018, section 12, and the cancer warning on alcohol

Ireland's 2018 alcohol law requires alcohol containers, pubs and online sellers to carry a warning about the direct link between alcohol and fatal cancers. The labelling rules made under it set the wording "There is a direct link between alcohol and fatal cancers".

Approvals

Ireland is an EU member state, so an EU centralised authorisation covers it: 309 products in OnCo carry a sourced EU row that is approved or conditional. See the approvals by region matrix. National procedures and reimbursement are not recorded.

What OnCo does not yet hold

No registry figures. The figures above are IARC's estimates; OnCo has not read Ireland's own cancer registry, its survival figures or its stage at diagnosis.
No payer detail: who pays for cancer care in Ireland, what a patient pays, and which medicines are reimbursed.
No regulator detail: the national medicines agency's own procedures, beyond EU centralised authorisations.
No national cancer plan, guideline, screening schedule or treatment-centre list read from Ireland's own sources.

A deep dive for Ireland is ranked 57 of 60 in the country coverage queue (November 2026), which ranks countries without a page by cases, deaths, research output and population. Know a source? Suggest an edit.

Sources and machine-readable data

IARC Global Cancer Observatory, GLOBOCAN 2024: Cancer Today.
ClinicalTrials.gov study records, courtesy of the US National Library of Medicine, as captured in each trial record.
OnCo records: each chip and card opens a record with its own sources.
This page as JSON: /api/v1/countries/ie.json; every country: /api/v1/countries.json.